Physician|BiotechExecutive |Public Health | Clinical Strategist
Joined March 2014
- Tweets 439
- Following 89
- Followers 1,875
- Likes 558
102 Photos and videos
Pinned Tweet
Honored to be listed in 2026 In Vivo’s Rising Leaders!!
insights.citeline.com/in-viv…
4
30
1,115
Big things ahead! ✨ Catch me as a Panelist at Clinical Trials at the Summit — June 13th, 2026, Las Vegas. Session: “The Inno-Circle: Opening the Doors to Innovation.” See you there! 🎤 #ClinicalTrials #Innovation
1
20
447
RT @Ocugen: What is the Ellipsoid Zone (EZ)? EZ is a structural biomarker for photoceptor integrity which correlates to visual function. Sh…
18
Kudos to clinical team and research staff for enrolling OCU410ST patients… one step closer to curing blindness.
Susan, an #OCU410ST participant, saw stabilization in her treated eye after #Stargardtdisease treatment, while the untreated eye declined. Now in Phase 2/3, OCU410ST could become the first approved therapy for Stargardt disease. Follow us for updates.
16
9
53
5,455
OCU410 Phase 2 Armada top line results.
#OCU410 Phase 2 ArMaDa topline results show:
• 31% ↓ GA lesion growth at 12 months vs. control
• ~2X treatment effect vs. approved therapies
• EZ preservation favorable safety
A one-and-done approach to reduce treatment burden.
🔗bit.ly/4c19g2f #GeographicAtrophy
1
13
82
2,985
Congratulations to Ocugen particularly my clinical team, investigators, patients and research staff in achieving this historic milestone.
With the successful completion of enrollment in the GARDian3 Phase 2/3 pivotal trial for Stargardt disease, Ocugen expects to file BLA by mid-2027.
Read more: bit.ly/4bLcNld
#Stargardt #GeneTherapy #InheritedRetinalDiseases #BlindnessDiseases
4
8
83
2,187
Proud to be a physician and creating a difference everyday!!
On #DoctorsDay, we thank the retinal surgeons advancing modifier gene therapy through their work in our clinical trials and serving as our advisors. Your work brings hope to patients facing major blindness diseases where few or no options exist. #GeneTherapy #Biotech
1
5
45
1,268
Live Webcast Phase 2 ArMaDa trial on 3/24
Ocugen will host a live webcast Mar 24 at 8 a.m. EDT on Phase 2 ArMaDa data for #OCU410 in GA, led by KOLs Lejla Vajzovic, MD, and Jay Chhablani, MD. Don’t miss key insights into advancements in modifier gene therapy for retinal disease.
Details: bit.ly/4uJ8GgG
18
70
3,678
International Women’s Day!!!
Celebrating the 115th anniversary of #InternationalWomensDay. We recognize the women of Ocugen whose expertise, leadership, and dedication help advance innovation and our mission to deliver transformative novel modifier gene therapies to patients. #IWD2026 #GiveToGain
1
3
39
1,119
OCU400 Limelight Trial enrollment completion and Phase1/2 3 year durability data!!
Enrollment is now complete for the Phase 3 liMeliGhT trial of #OCU400 for #retinitispigmentosa, the first and largest gene therapy registrational trial for broad RP patients. Ocugen remains on track to file a rolling BLA in 3Q 2026. #Biotech
Read more: bit.ly/4lcvktK
3
16
82
3,259
Rare Disease Day 2026!!!
We support @RareDiseaseDay! At Ocugen, we are committed to advancing our novel modifier gene therapies for rare inherited retinal diseases with significant unmet needs. We stand with patients, families, and the global #raredisease community, today and every day.
12
50
1,319
Macula Society 2026!!!
Dr. Gonzalez will present “Safety and Preliminary Efficacy of OCU410ST for Stargardt Disease: Phase 1 Results Update” at the 49th Annual Macula Society Meeting on behalf of Ocugen on Friday, Feb 27, 2026 from 7–7:05 a.m. PST. #GeneTherapy
Learn more: bit.ly/4ruCf3R
1
14
62
1,644
OCU400 patient testimonial !!
During #RetinitisPigmentosaAwarenessMonth, the need for new treatments is clear. We are advancing #OCU400, our lead modifier gene therapy candidate, and plan to begin the BLA submission this year. Learn about Manny’s journey: bit.ly/4aQL9Bw
#GeneTherapy #Biotech
1
18
79
3,669
Trending first time Phase 2 preliminary data for OCU410 GA trial
Phase 2 #ArMaDa trial: OCU410 showed a 57% reduction in medium dose and 56% reduction in high dose in lesion growth in patients with baseline GA ≥7.5 mm², suggesting strong benefit in those with more advanced disease. #AMDAwarenessMonth @PBA_savingsight🔗bit.ly/3ZHoMsY
3
19
84
3,343
International Day of Women and Girls in Science.
Today is International Day of Women and Girls in Science. Let’s work together to build a bright future for women and girls in STEM, celebrating those driving discovery today while encouraging the next generation of female scientists. #February11 #CourageousInnovation
2
30
1,125
Ocugen, Inc announces pricing of $22.5 million offering of common stock!!
ir.ocugen.com/news-releases/…
3
4
43
2,368
Fierce Biotech Armada Results!
fiercebiotech.com/biotech/oc…
3
18
69
2,247